CapsoVision executives to attend upcoming investor conferences, presenting their advanced imaging and AI-enabled capsule endoscopy solutions.
Quiver AI Summary
CapsoVision, Inc., a medical technology company specializing in advanced imaging and AI-enhanced capsule endoscopy solutions, has announced participation in two upcoming investor conferences: the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16 in New York City and the 5th Annual ROTH Healthcare Opportunities Conference on September 29. Key executives, including CEO Johnny Wang, will present on-demand content and engage in one-on-one investor meetings. The on-demand presentation will be accessible on the company's investor relations website for 90 days. CapsoVision's flagship product, the CapsoCam Plus®, facilitates high-resolution imaging of the small bowel, while its upcoming CapsoCam Colon™ aims to improve non-invasive colon imaging and polyp detection. For further details, interested parties can contact the company directly.
Potential Positives
- The participation of senior executives in prominent investor conferences demonstrates CapsoVision's commitment to engaging with the investment community and showcasing its advancements in medical technology.
- The announcement of the on-demand company presentation indicates transparency and provides an opportunity for broader audience engagement, potentially attracting new investors.
- The company's focus on innovative products, such as the CapsoCam Plus® and the upcoming CapsoCam Colon™, signals strong growth potential in the gastrointestinal diagnostics market.
Potential Negatives
- The press release lacks specific information about the company's recent performance or financial health, which could raise concerns among investors about its stability and growth potential.
FAQ
What upcoming investor conferences will CapsoVision attend?
CapsoVision will participate in the H.C. Wainwright 28th Annual Global Investment Conference and the 5th Annual ROTH Healthcare Opportunities Conference.
When is CapsoVision's on-demand presentation available?
The on-demand presentation will be available starting September 11, 2026, for 90 days on the company's investor relations website.
How can I arrange a meeting with CapsoVision's management?
You can arrange a 1x1 meeting by contacting H.C. Wainwright and Roth representatives or by emailing [email protected].
What products does CapsoVision offer?
CapsoVision's flagship product is the CapsoCam Plus®, a panoramic capsule endoscope, and they are developing the CapsoCam Colon™ for colon imaging.
What is CapsoVision's focus area in medical technology?
CapsoVision focuses on advanced imaging and AI-enabled solutions to improve the detection and screening of gastrointestinal diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CV Insider Trading Activity
$CV insiders have traded $CV stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CV stock by insiders over the last 6 months:
- ELIYAHOU ET AL HARARI has made 3 purchases buying 156,218 shares for an estimated $1,007,915 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CV Hedge Fund Activity
We have seen 35 institutional investors add shares of $CV stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 591,667 shares (+45.4%) to their portfolio in Q2 2026, for an estimated $4,484,835
- STATE STREET CORP added 154,200 shares (+60.2%) to their portfolio in Q2 2026, for an estimated $1,168,836
- GEODE CAPITAL MANAGEMENT, LLC added 143,328 shares (+32.9%) to their portfolio in Q2 2026, for an estimated $1,086,426
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 79,360 shares (+inf%) to their portfolio in Q2 2026, for an estimated $601,548
- NORTHERN TRUST CORP added 67,761 shares (+44.5%) to their portfolio in Q2 2026, for an estimated $513,628
- UBS GROUP AG removed 57,859 shares (-88.8%) from their portfolio in Q2 2026, for an estimated $438,571
- XTX TOPCO LTD removed 35,536 shares (-52.7%) from their portfolio in Q2 2026, for an estimated $269,362
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor conferences:
H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City)
- Format: On-demand Company Presentation and 1x1 Investor Meetings
-
Date/Time:
- On-demand Company Presentation – Friday, September 11, 2026, beginning at 7:00 am ET
-
1x1 Investor Meetings – Monday, September 14, 2026
5th Annual ROTH Healthcare Opportunities Conference (September 29 in New York City)
- Format: 1x1 Investor Meetings
-
Date/Time: Tuesday, September 29, 2026
The on-demand presentation will be available on the Events page in the investor relations section of the company’s website for 90 days. If you are interested in arranging a one-on-one meeting with CapsoVision’s management team at the conferences, please contact your respective H.C. Wainwright and Roth representatives or reach out to the company directly at [email protected] .
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com .
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
[email protected]
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
[email protected]
| (804) 240-0807
[email protected]
| (804) 503-9231
